As a promising drug, the setback for Alzheimer’s disease has no benefit in clinical trials


Attempts to develop drugs to treat Alzheimer’s disease have experienced a new setback, a promising drug that failed to show the benefits of the latest series of clinical trials.

Earlier tests showed that idalopirdine, a drug from Danish international pharmaceutical company Lundbeck, may improve cognition in patients with Alzheimer’s disease and may be used with existing drugs (known as cholinesterase inhibitors) to improve symptoms , Not to stop the disease from developing. But recent experiments have lost that promise.

Professor Clive Ballard, co-author of the University of Exeter study, said: “I am personally very excited, pointing out that the previous trial looked promising.” It is very disappointing , Then no pan “.
In an international team report in the Journal of the American Medical Association, they reported on how they conducted a total of 2525 participants in 34 clinical trials in three countries to explore the effects of idalopirdine. All participants were over 50 years of age with mild to moderate Alzheimer’s disease.

In all trials, participants were randomly assigned to receive either specific doses of idalopirdine or placebo, and were treated with existing Alzheimer’s drugs when patients and scientists were not aware of the time each participant was in. All three trials last 24 weeks.
The results were disappointing, revealing that the new drug did not matter in terms of increasing cognitive ability or limiting participants’ decline, regardless of dose. The authors wrote: “These findings do not support the use of idalopirdine in the treatment of Alzheimer’s disease.

Ballard said: “I think this is a very big blow, although he pointed out that these trials have some limitations, including placebo participants did not show any decline over time, indicating that the choice of participants Potential benefits may be at least partially obscured, with the maximum daily dose of idarubes given lower than in previous trials, in part to avoid the negative effects on the liver.

More importantly, participants do not need to test biomarker Alzheimer’s disease such as PET scans or cerebrospinal fluid analysis, which means that some patients may not have amyloid blocks in the brain.

Ballard added that to determine the benefits of idalopirdine, data on greater risk reduction from participants should be re-analyzed, such as those who already have a scan showing amyloid blocks. He said: “I think (idalopirdine) is almost dead at the moment, but maybe just a little due diligence before logging out.

Pfizer’s pharmaceutical giant announced that it is concluding its treatment study for Alzheimer’s disease and Parkinson’s disease and shifting funds to other areas.

Dr. James Pickett, head of the Alzheimer’s Association, said disappointing the failure of idalopirdine to improve cognitive function in people with Alzheimer’s disease.
“Last year’s news showed that there is no benefit to a drug that works in a similar way, a drug, and these results suggest that this type of drug may not have the effect we expect in patients with Alzheimer’s disease, and we We need to expand our focus. “He added that despite recent actions, research will still find new treatments and he still has hopes of Pfizer.

“The advances in technology mean that we have begun to see signs of Alzheimer’s disease in our living brain and researchers can be confident that those who participate in the trial will certainly be affected by Alzheimer’s rather than those with similar symptoms – It may be one of them, he added. “Such a technological breakthrough will greatly improve the way we conduct clinical trials of Alzheimer’s disease and bring great hope for finding new treatments in the future.”


Please enter your comment!
Please enter your name here